This report forecasts to 2023 US kidney dialysis center revenue in nominal US dollars. The total population and point-prevalence of end-stage renal disease (ESRD) are also forecast to 2023. Total revenue is segmented by the source in terms of patient care (government; private insurance; out-of-pocket; and other sources, such as charitable contributions, gifts, and grants), and non-patient care and all other sources (such as administrative services, incentive fees, management fees, and medical director fees).
Total population, as well as point-prevalence of ESRD, kidney transplants, hemodialysis patients, and peritoneal dialysis patients, are segmented by age cohort as follows: 0-9, 10-29, 30-49, 50-64, 65-74, and 75+.
To illustrate historical trends, total revenue, population, point-prevalence of ESRD, kidney transplants, hemodialysis patients, peritoneal dialysis patients, and the various segments are provided in annual series from 2008 to 2018.
Key macroeconomic indicators are also provided with quantified trends. Other various topics, including profiles of pertinent leading suppliers, are covered in this report.
Table of Contents
Companies Mentioned
- DaVita
- Fresenius
- US Renal Care
Methodology
LOADING...
